Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. (Q45790066)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. (English)

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Espen A Haavardsholm

10

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Anna-Birgitte Aga

1

object named as

Anna-Birgitte Aga

0 references

9

object named as

Tore K Kvien

1 reference

Europe PubMed Central

16 December 2017

Inge Christoffer Olsen

4

object named as

Inge Christoffer Olsen

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

7

object named as

Erik Rødevand

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Synøve Kalstad

6

object named as

Synøve Kalstad

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

author name string

Anna-Birgitte Aga

1

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Elisabeth Lie

2

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Ada Wierød

5

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Knut Mikkelsen

8

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

language of work or name

0 references

publication date

27 November 2013

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

74

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

2

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

381-388

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Inequities in access to biologic and synthetic DMARDs across 46 European countries

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

The estimation of a preference-based measure of health from the SF-36.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Clinical outcome measures in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

The definition and measurement of disease modification in inflammatory rheumatic diseases

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204020

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-204020

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24285493

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45790066&oldid=1744871736"